Search Result

Results for "

psoriatic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (3) Aryl Hydrocarbon Receptor (1) Bacterial (1) Cannabinoid Receptor (1) CXCR (1) DNA/RNA Synthesis (4) Endogenous Metabolite (3) Epigenetic Reader Domain (1) FABP (1) Fungal (2) HDAC (1) Histone Acetyltransferase (1) Interleukin Related (15) IRAK (2) Leukotriene Receptor (1) Lipoxygenase (1) Na+/K+ ATPase (1) NF-κB (1) Phosphodiesterase (PDE) (2) PKC (1) PPAR (1) Reference Standards (1) SARS-CoV (1) STAT (1) TNF Receptor (3) VISTA (1)
By Research Areas:	Cancer (4) Infection (6) Inflammation/Immunology (29) Metabolic Disease (2) Neurological Disease (1)

By Targets:

Antibiotic (1)

Apoptosis (3)

Aryl Hydrocarbon Receptor (1)

Bacterial (1)

Cannabinoid Receptor (1)

CXCR (1)

DNA/RNA Synthesis (4)

Endogenous Metabolite (3)

Epigenetic Reader Domain (1)

FABP (1)

Fungal (2)

HDAC (1)

Histone Acetyltransferase (1)

Interleukin Related (15)

IRAK (2)

Leukotriene Receptor (1)

Lipoxygenase (1)

Na+/K+ ATPase (1)

NF-κB (1)

Phosphodiesterase (PDE) (2)

PKC (1)

PPAR (1)

Reference Standards (1)

SARS-CoV (1)

STAT (1)

TNF Receptor (3)

VISTA (1)

By Research Areas:

Cancer (4)

Infection (6)

Inflammation/Immunology (29)

Metabolic Disease (2)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0738

Dithranol Anthralin	DNA/RNA Synthesis	Inflammation/Immunology
Dithranol (Anthralin) is an anthraquinone derivative, with potent anti-psoriatic effects. Dithranol can inhibit DNA replication and repair .

HY-P99310

Perakizumab RG4934	Interleukin Related	Inflammation/Immunology
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .

HY-P99335

Vunakizumab Anti-Human IL17A Recombinant Antibody	Interleukin Related	Inflammation/Immunology
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .

HY-P99754

Netakimab	Interleukin Related	Inflammation/Immunology
Netakimab is an anti-IL-17 IgG1 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P9931

Guselkumab CNTO 1959	Interleukin Related	Inflammation/Immunology
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with K_d values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .

HY-P99012

Clazakizumab	Interleukin Related SARS-CoV	Infection Inflammation/Immunology
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection .

HY-151363

IRAK4-IN-21	IRAK	Inflammation/Immunology
IRAK4-IN-21 (compound 17) is an orally active, potent and selective IRAK4 inhibitor with IC₅₀ values of 5 and 56 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.17 μM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .

HY-B0738R

Dithranol (Standard)	DNA/RNA Synthesis	Inflammation/Immunology
Dithranol (Standard) is the analytical standard of Dithranol. This product is intended for research and analytical applications. Dithranol (Anthralin) is an anthraquinone derivative, with potent anti-psoriatic effects. Dithranol can inhibit DNA replication and repair .

HY-169853

M351-0056	VISTA	Inflammation/Immunology
M351-0056 is the agonist for the immune checkpoint protein VISTA, that reduces the secretion of VISTA-induced cytokines, promotes the T-cell proliferation induced by VISTA, and exhibits immunomodulatory activity. M351-0056 ameliorates Imiquimod (HY-B0180)-induced psoriatic dermatitis in mouse models .

HY-155243

12R-LOX-IN-1	DNA/RNA Synthesis	Inflammation/Immunology
12R-LOX-IN-1 (Compound 4a) is a 12R-LOX inhibitor (IC₅₀: 28.25 μM). 12R-LOX-IN-1 inhibits the hyper-proliferative state and colony forming potential of Imiquimod (HY-B0180)-induced psoriatic keratinocytes. 12R-LOX-IN-1 inhibits reactive oxygen species, Ki67, IL-17A, TNF-α and IL-6 production. 12R-LOX-IN-1 can be used for antipsoriatic research .

HY-151365

IRAK4-IN-22	IRAK	Inflammation/Immunology
IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC₅₀ values of 3 and 17 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .

HY-158159

IL17A-IN-1	Interleukin Related	Inflammation/Immunology Cancer
IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer .

HY-P99378

Neihulizumab ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab)	Apoptosis	Inflammation/Immunology
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .

HY-N2414

Periplogenin 1 Publications Verification	Others	Inflammation/Immunology
Periplogenin is a naturally occurring furanocoumarin found in Angelica dahurica roots, with potent anti-psoriatic effects. Periplogenin induces adipocyte differentiation .

HY-N1579

Pyrogallol 3 Publications Verification	Endogenous Metabolite Fungal Apoptosis	Infection
Pyrogallol is a polyphenol compound, which has anti-fungal and anti-psoriatic properties. Pyrogallol is a reductant that is able to generate free radicals, in particular superoxide anions.

HY-113884A

(±)-Coriolic acid (±)-13-HODE	Endogenous Metabolite	Metabolic Disease
(±)13-HODE is one of the two racemic monohydroxy fatty acids resulting from the non-enzymatic oxidation of linoleic acid. It is the principle hydroxylated fatty acid in human psoriatic skin scales, with a mean concentration of 17 ng/mg.

HY-N1579R

Pyrogallol (Standard)	Reference Standards Endogenous Metabolite Fungal Apoptosis	Infection
Pyrogallol (Standard) is the analytical standard of Pyrogallol. This product is intended for research and analytical applications. Pyrogallol is a polyphenol compound, which has anti-fungal and anti-psoriatic properties. Pyrogallol is a reductant that is able to generate free radicals, in particular superoxide anions.

HY-100365

Remetinostat SHP-141	HDAC	Inflammation/Immunology Cancer
Remetinostat (SHP-141) is a hydroxamic acid-based histone deacetylase (HDAC) inhibitor. Remetinostat alleviates Imiquimod (HY-B0180)-induced psoriatic dermatitis. Remetinostat can be used for study of cutaneous T-cell lymphoma .

HY-P9927

Secukinumab 2 Publications Verification AIN457	Interleukin Related	Inflammation/Immunology Cancer
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .

HY-141535A

IL-17 modulator 1 disodium	Interleukin Related	Infection Inflammation/Immunology
IL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator extracted from patent WO 2020127685. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .

HY-168212

PDE4-IN-22	Phosphodiesterase (PDE) TNF Receptor Interleukin Related	Inflammation/Immunology
PDE4-IN-22 (Compound 2e) is a PDE4 inhibitor with an IC₅₀ value of 2.4 nM. PDE4-IN-22 exhibits anti-inflammatory activity and demonstrates significant anti-psoriatic effects in an Imiquimod (HY-B0180)-induced psoriasis mouse model .

HY-141535

IL-17 modulator 1	Interleukin Related	Infection Inflammation/Immunology
IL-17 modulator 1 is an orally active, highly efficacious small molecule IL-17 modulators extracted from patent WO 2020127685. IL-17 modulator 1 can be used for the research of preventing, researching or ameliorating a variety of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .

HY-124099

SCH 40120	Leukotriene Receptor	Inflammation/Immunology
SCH 40120 is a potent leukotriene inhibitor with antiinflammatory effects. SCH 40120 suppresses T cell proliferative responses, antigen-specific and poly-clonally-induced in vitro antibody responses. SCH 40120 suppresses an edematous response and inhibits the recruitment of circulating neutrophils into sites of inflammation. SCH 40120 is proming for rasearch of anti-psoriatic agents .

HY-169306

IL-17A inhibitor 4	Interleukin Related	Inflammation/Immunology
IL-17A inhibitor 4 (Example 449) is a potent IL-17A inhibitor. IL-17A inhibitor 4 inhibits HTRF and NHK cells viability with IC₅₀s of 0.028 and 0.0047 μM, respectively .

HY-124404

12(R)-HETE	Na+/K+ ATPase Aryl Hydrocarbon Receptor	Others Inflammation/Immunology
12(R)-HETE is a metabolite of Arachidonic acid, AA (HY-109590) and can be found in skin from psoriatic lesions. 12(R)-HETE induces lymphocytes chemotaxis, stimulates calcium mobilization and chemotaxis in neutrophils via the BLT1 receptor, activates the aryl hydrocarbon receptor, and inhibits Na+/K+ ATPase activity in the corneal epithelium .

HY-P99248

Risankizumab Risankizumab rzaa; BI 655066	Interleukin Related	Inflammation/Immunology
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (K_d <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC₅₀ = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .

HY-159115

ART26.12	FABP Cannabinoid Receptor PPAR NF-κB PKC	Neurological Disease Metabolic Disease Inflammation/Immunology
ART26.12 is a potent, selective and orally active inhibitor of FABP5. ART26.12 can regulate lipid metabolism and activate cannabinoid receptors. ART26.12 has analgesic effects and can be used in the research of diseases such as peripheral neuropathy and psoriasis .

HY-P99940

Remtolumab ABT-122	TNF Receptor Interleukin Related	Inflammation/Immunology
Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research .

HY-155244

12R-LOX-IN-2	Lipoxygenase DNA/RNA Synthesis	Inflammation/Immunology
12R-LOX-IN-2 (compound 7b) is an inhibitor of 12R-lipoxygenase (12R-LOX). 12R-LOX-IN-2 inhibits imiquimod (IMQ)-induced hyperproliferation of psoriatic keratinocytes and suppresses colony formation. 12R-LOX-IN-2 also reduced the protein level of Ki67 and the mRNA expression of IL-17A in IMQ-induced cells. 12R-LOX-IN-2 can be used in research into psoriasis and other skin-related inflammatory diseases .

HY-P10587

Icotrokinra JNJ-77242113; JNJ-2113; PN-235	Interleukin Related STAT	Inflammation/Immunology
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC₅₀=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC₅₀ of 18.4 pM. In addition, Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .

HY-P2313

Human β-defensin-2 HβD-2	Antibiotic Bacterial	Infection
Human β-defensin-2 (HβD-2) is a small cysteine-rich cationic skin-antimicrobial peptide (SAP) produced by a number of epithelial cells.Human β-defensin-2 has antimicrobial activity against gram-negative bacteria and Candida, but not gram-positive Staphylococcus aureus . Human β-defensin-2 can be used for the study of colitis .

HY-15826

SGC-CBP30 Maximum Cited Publications 15 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Inflammation/Immunology Cancer
SGC-CBP30 is a potent and highly selective CBP/p300 bromodomain (K_ds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .

HY-173290

PDE4D inhibitor 1	Phosphodiesterase (PDE) Interleukin Related CXCR TNF Receptor	Inflammation/Immunology
PDE4-IN-1 is a PDE4 inhibitor with high potency (IC₅₀ : 8.6 nM) and selectivity over other PDE subtypes. PDE4-IN-1 inhibits the release of inflammatory cytokines and chemokines. PDE4-IN-1 greatly restores impaired cAMP-CREB signaling pathway. PDE4-IN-1 inhibits proliferation and promotes differentiation to reverse the formation of psoriasis .

Cat. No.	Product Name	Target	Research Area